Alpelisib, Fulvestrant and Dapagliflozin for the Treatment of HR+, HER2 -, PIK3CA Mutant Metastatic Breast Cancer
Clinical trial NCT05025735 · UNKNOWN
Trial details
- NCT number
- NCT05025735
- Sponsor
- Saint Luke's Health System
- Status
- UNKNOWN
- Phase
- Phase 2
- Study type
- INTERVENTIONAL
- Start date
- 2021-08-25
- Primary completion
- 2022-12-01
- Enrollment
- 25
Track trials programmatically
Sponsors, conditions and status changes through the Atlas API.